Investor Relations Overview

Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. Rezolute is advancing a diversified pipeline including: RZ358 (Phase 2), an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy; AB101 (Phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds, RZ402 (plan to file IND in H2 2018) targeting Diabetic Macular Edema (DME) and RZ602 (plan to file IND in H1 2019) targeting Hereditary Angioedema (HAE), an orphan indication.

Corporate Presentation - Q3 2018

Recent News

• May 16, 2018 Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
• Apr 9, 2018 Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
• Apr 4, 2018 Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors